Article
Immunology
Adriana Margarit-Soler, Angela Deya-Martinez, Juan Torres Canizales, Alexandru Vlagea, Ana Garcia-Garcia, Julia Marsal, Maria Trabazo Del Castillo, Silvia Planas, Silvia Simo, Ana Esteve-Sole, Maria Suarez-Lledo Grande, Isabel Badell, Montserrat Rovira Tarrats, Francesc Fernandez-Aviles, Laia Alsina
Summary: CTLA-4 haploinsufficiency is a T-cell hyperactivation disorder that can cause immunodeficiency and immune dysregulation. HSCT is a potentially curable treatment for treatment-resistant immune dysregulation, but there is limited experience in managing complications post-HSCT.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Clara Sattler, Petra Hoffmann, Philipp Yorck Herzberg, Daniela Weber, Barbara Holler, Ute Fehn, Annelie Plentz, Philipp Beckhove, Julia Winkler, Matthias Edinger, Wolfgang Herr, Ernst Holler, Daniel Wolff
Summary: A retrospective study analyzed predictors of immune response to primary vaccination in alloHSCT patients, showing that a majority of patients achieved protective titers to DTaP-Hib-IPV vaccine, but some patients had inadequate immune response.
Article
Immunology
Dina Leth Moller, Katrine Kielsen, Claus Henrik Nielsen, Henrik Sengelov, Anders Elm Pedersen, Lars Peter Ryder, Klaus Muller
Summary: This study suggests a role of TSLP in immune reconstitution and alloreactivity post-HSCT.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
(2022)
Article
Immunology
Hongfeng Huang, Qixia Shen, Jingyi Zhou, Xiuyan Yang, Qiuqin Cai, Jia Shen, Shi Feng, Wenqing Xie, Hong Jiang, Jianghua Chen
Summary: The clinical experience demonstrates the efficacy of non-myeloablative conditioning protocol in inducing tolerance in HLA identical patients, and complete chimerism may be a risk factor for GVHD.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Alex E. Wolfe, Kate A. Markey
Summary: Allogenic hematopoietic stem-cell transplantation is an immunotherapy for high-risk hematological malignancies and immune deficiencies. Immune recovery and the relationship with gut microbiome are important factors for transplant outcomes.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Richard J. Lin, Harold K. Elias, Marcel R. M. van den Brink
Summary: Older patients with hematologic malignancies are increasingly undergoing allogeneic hematopoietic cell transplantation, with aging-related thymic dysfunction and other aging hallmarks potentially impacting immune reconstitution post-transplantation. Mechanism-based therapeutic interventions are being discussed to address these issues.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Jiayu Wang, Meng Yuan, Guanghua Zhu, Runhui Wu, Chenguang Jia, Bin Wang, Jie Zheng, Jie Ma, Maoquan Qin, Sidan Li
Summary: This study analyzed the immune reconstitution of pediatric patients with aplastic anemia after hematopoietic stem-cell transplantation (HSCT) and found that early rapid immune reconstitution is a good predictor of clinical prognosis in children with AA.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
(2022)
Article
Immunology
Anna Soderstrom, Sofie Vonlanthen, Kerstin Jonsson-Videsater, Stephan Mielke, Hannes Lindahl, Johan Torlen, Michael Uhlin
Summary: This study found that measuring TREC levels can predict the prognosis of adult AML patients after bone marrow transplantation, especially overall survival. Lower TREC levels were associated with viral infections and CMV reactivation. KREC levels were not associated with clinical outcomes.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Xuxu Zhao, Wenya Wang, Shiqin Nie, Liangquan Geng, Kaidi Song, Xinyi Zhang, Wen Yao, Ping Qiang, Guangyu Sun, Dongyao Wang, Huilan Liu
Summary: Umbilical cord blood transplantation (UCBT) and peripheral blood stem cell transplantation (PBSCT) are effective treatments for hematological diseases. However, there are differences in the immune reactions and cell reconstitution between UCBT and PBSCT. This study analyzed these differences in early stages post-transplantation and found that UCBT group had higher incidences of immune reactions and different immune cell proportions compared to PBSCT group.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Anne-Marie Daull, Valerie Dubois, Helene Labussiere-Wallet, Fabienne Venet, Fiorenza Barraco, Sophie Ducastelle-Lepretre, Marie-Virginie Larcher, Marie Balsat, Lila Gilis, Gaelle Fossard, Herve Ghesquieres, Mael Heiblig, Florence Ader, Vincent Alcazer
Summary: This study analyzed the impact of class I and II HED on acute myeloid leukemia recipients undergoing HCT. It found that a high class I HED had a positive impact on disease-free survival and overall survival, while a high class II HED had a negative impact. The class I/class II HED ratio was identified as an independent prognosis marker for both DFS and OS.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Maria Teresa Cencioni, Angela Genchi, Gavin Brittain, Thushan I. de Silva, Basil Sharrack, John Andrew Snowden, Tobias Alexander, Raffaella Greco, Paolo A. Muraro
Summary: Multiple sclerosis (MS) is a central nervous system disorder characterized by inflammation, demyelination, and axonal loss. Autologous hematopoietic stem cell transplantation (HSCT) has shown promising results in achieving long-term clinical remission in highly active MS patients by eradicating autoreactive cells and restoring immune tolerance. Further research is needed to understand the mechanisms behind the effectiveness of HSCT and to study the reconstitution of immunological memory following the treatment. Additionally, evaluating the efficacy and safety of vaccination in HSCT-treated subjects can provide insights into immune responses and distinguish between broad immunosuppression and immune resetting.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Xiao-Hua Luo, Yan Zhu, Yu-Ting Chen, Li-Ping Shui, Lin Liu
Summary: Haploidentical stem cell transplantation has become a common procedure for treating patients with hematological malignancies and immunodeficiency diseases, but is hindered by CMV infections and delayed immune reconstitution. Three major approaches for haploSCT are currently used worldwide, and progress has been made in cellular immunotherapy of CMV infection post-transplantation. Groundwork has been laid for personalized approaches to enhance immune reconstitution and decrease the incidence of CMV infection after haploSCT.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Martina Hinterleitner, Clemens Hinterleitner, Elke Malenke, Birgit Federmann, Ursula Holzer, Martin Mueller, Wolfgang A. Bethge, Stefan Wirths
Summary: Reconstitution of immune cells after stem cell transplantation takes place in different stages. This study investigated the formation of new B cells in patients who received haploidentical stem cell transplantation with CD3 and CD19 depletion. It was found that antibody-secreting cells (ASC) reconstituted very early, before the detection of naive and memory B cells.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Cell Biology
Maria Florencia Tellechea, Flavia S. Donaires, Vinicius S. de Carvalho, Barbara A. Santana, Fernanda B. da Silva, Raissa S. Tristao, Lilian F. Moreira, Aline F. de Souza, Yordanka M. Armenteros, Lygia Pereira, Rodrigo T. Calado
Summary: This study used iPSCs to model immune aplastic anemia and found that the differentiation potential of hematopoietic cells in this disease is significantly reduced, suggesting that specific epigenetic changes in HSPCs caused by immune attack may limit cell proliferation and differentiation.
CELL DEATH & DISEASE
(2022)
Article
Biotechnology & Applied Microbiology
Sybille Landwehr-Kenzel, Leonie Mueller-Jensen, Joern-Sven Kuehl, Mohamed Abou-el-Enein, Henrike Hoffmann, Sandra Muench, Daniel Kaiser, Andy Roemhild, Horst von Bernuth, Mirjam Voeller, Michael Schmueck-Henneresse, Bernd Gruhn, Ulrik Stervbo, Nina Babel, Hans-Dieter Volk, Petra Reinke
Summary: This study explored the use of adoptive transfer of ex vivo expanded regulatory T cells (Tregs) for the treatment of chronic graft-versus-host disease (GvHD). The results showed that Tregs therapy was well tolerated and capable of modulating established adverse T cell mediated allo-response in patients.
Review
Cell Biology
Guilhem Lalle, Julie Twardowski, Yenkel Grinberg-Bleyer
Summary: NF-kappa B plays a crucial role in immune responses to cancer and could be targeted by novel immunotherapies.
Review
Nanoscience & Nanotechnology
Benedetta Ferrara, Sabrina Belbekhouche, Damien Habert, Claire Houppe, Benoit Vallee, Sandrine Bourgoin-Voillard, Jose L. Cohen, Ilaria Cascone, Jose Courty
Summary: Nanoparticles are being studied as a targeted delivery system for cancer treatment, with nucleolin identified as an interesting therapeutic target. Antagonists of nucleolin from various sources have shown promise as potential anti-cancer agents.
Article
Microbiology
Christophe Rodriguez, Nicolas de Prost, Slim Fourati, Claudie Lamoureux, Guillaume Gricourt, Melissa N'debi, Florence Canoui-Poitrine, Isaac Desveaux, Oriane Picard, Vanessa Demontant, Elisabeth Trawinski, Raphael Lepeule, Laure Surgers, William Vindrios, Jean-Daniel Lelievre, Nicolas Mongardon, Olivier Langeron, Jose L. Cohen, Armand Mekontso-Dessap, Paul-Louis Woerther, Jean-Michel Pawlotsky
Summary: This study utilized shotgun metagenomics and in-depth bioanalysis to investigate the role of viral genomics, microorganism metagenomics, and host transcriptomics in the severity of COVID-19. Severe COVID-19 pneumonia was associated with overexpression of cytokine transcripts activating the CXCR2 pathway, while patients with benign disease presented with a specific T cell profile and a lower mortality rate. Excess neutrophil infiltration leading to enhanced inflammatory response and prolonged tissue damage was identified as a key factor in the most severe cases of COVID-19. The study suggests that CXCR2 antagonists, especially IL-8 antagonists, could be promising candidates for treating severe COVID-19 patients.
Review
Immunology
Lucille Adam, Pierre Rosenbaum, Olivia Bonduelle, Behazine Combadiere
Summary: Immunomonitoring involves studying immune responses during vaccination or infection, with a focus on viral control or vaccine efficacy. Traditional methods include easy-to-use antibody-based technologies, while modern high-throughput technologies allow holistic approaches but also raise challenges in data integration methods and tools.
Article
Immunology
Manon Chauvin, Martin Larsen, Bibiana Quirant, Paul Quentric, Karim Dorgham, Luca Royer, Helene Vallet, Amelie Guihot, Behazine Combadiere, Christophe Combadiere, Jaume Barallat, Julien Mayaux, Charles-Edouard Luyt, Alexis Mathian, Zahir Amoura, Jacques Boddaert, Fernando Armestar, Guy Gorochov, Eva Martinez-Caceres, Delphine Sauce
Summary: This study found that severe and critically ill patients with SARS-CoV-2 infection exhibit exacerbated immune activation characterized by elevated neopterin blood levels. Systemic neopterin levels can serve as a biomarker of severe Covid-19, helping to identify high-risk populations.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2021)
Article
Immunology
Judith Del Campo, Julien Bouley, Marion Chevandier, Carine Rousset, Marjorie Haller, Alice Indalecio, Delphine Guyon-Gellin, Alexandre Le Vert, Fergal Hill, Sophia Djebali, Yann Leverrier, Jacqueline Marvel, Behazine Combadiere, Florence Nicolas
Summary: OVX836, a recombinant protein vaccine, induces a strong immune response through intramuscular injection, resulting in a high number of IFN- γ-producing CD8 + T-cells and lung TRM CD8 + T-cells for long-term protection against influenza viruses.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Behazine Combadiere, Lucille Adam, Noelline Guillou, Paul Quentric, Pierre Rosenbaum, Karim Dorgham, Olivia Bonduelle, Christophe Parizot, Delphine Sauce, Julien Mayaux, Charles-Edouard Luyt, Alexandre Boissonnas, Zahir Amoura, Valerie Pourcher, Makoto Miyara, Guy Gorochov, Amelie Guihot, Christophe Combadiere
Summary: Neutrophil subsets in COVID-19 patients have prognostic value in predicting disease severity and thrombosis complications.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, Research & Experimental
Lucille Adam, Pierre Rosenbaum, Paul Quentric, Christophe Parizot, Olivia Bonduelle, Noelline Guillou, Aurelien Corneau, Karim Dorgham, Makoto Miyara, Charles-Edouard Luyt, Amelie Guihot, Guy Gorochov, Christophe Combadiere, Behazine Combadiere
Summary: This study identified specific T cell populations associated with survival or death in COVID-19 patients in intensive care, providing potential targets for T cell-based vaccine development and disease outcome prediction.
Editorial Material
Medicine, Research & Experimental
Lara Revol-Bauz, Yenkel Grinberg-Bleyer
M S-MEDECINE SCIENCES
(2022)
Review
Cell Biology
Audrey Moatti, Jose L. Cohen
Summary: Newly discovered anti-cancer immunotherapies focus on stimulating anti-tumor T cell responses, but a significant proportion of patients do not respond. A novel approach proposes targeting the suppressive action of Tregs on anti-tumoral responses. TNFR2 has emerged as a legitimate target for anti-cancer immune checkpoint therapy, showing potential in overcoming the immune suppression in cancer patients.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Maud Plaschka, Valentin Benboubker, Maxime Grimont, Justine Berthet, Laurie Tonon, Jonathan Lopez, Myrtille Le-Bouar, Brigitte Balme, Garance Tondeur, Arnaud de la Fouchardiere, Lionel Larue, Alain Puisieux, Yenkel Grinberg-Bleyer, Nathalie Bendriss-Vermare, Bertrand Dubois, Christophe Caux, Stephane Dalle, Julie Caramel
Summary: This study reveals that ZEB1 expression in melanoma cells is associated with decreased CD8(+) T cell infiltration, leading to tumor immune evasion and resistance to immune checkpoint blockade. ZEB1 directly represses the secretion of T cell-attracting chemokines, such as CXCL10, and targeting ZEB1 may enhance the efficacy of immunotherapy in melanoma.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Matteo Ponzo, Anais Debesset, Melissande Cossutta, Mounira Chalabi-Dchar, Claire Houppe, Caroline Pilon, Alba Nicolas-Boluda, Sylvain Meunier, Fabio Raineri, Allan Thiolat, Remy Nicolle, Federica Maione, Serena Brundu, Carina Florina Cojocaru, Philippe Bouvet, Corinne Bousquet, Florence Gazeau, Christophe Tournigand, Jose Courty, Enrico Giraudo, Jose L. Cohen, Ilaria Cascone
Summary: This study explores the effects of a selective inhibitor of nucleolin (NCL) on the immune microenvironment of pancreatic ductal adenocarcinoma (PDAC), and highlights a new therapeutic strategy to restrain immunosuppressive cells, promote T-cell recruitment and activation, and re-program the tumor stroma of PDAC.
Article
Oncology
Anthony Di Roio, Margaux Hubert, Laurie Besson, Marion Bossennec, Celine Rodriguez, Yenkel Grinberg-Bleyer, Guilhem Lalle, Lyvia Moudombi, Raphael Schneider, Cyril Degletagne, Isabelle Treilleux, Daniel J. Campbell, Severine Metzger, Thomas Duhen, Olivier Tredan, Christophe Caux, Christine Menetrier-Caux
Summary: This study investigated the expression, function, and regulation of MDR1 in CD4(+) T cells and its role in neoadjuvant chemotherapy in breast cancer. The results showed that MDR1 expression was associated with the enrichment of Th1.17 and Th17 cells and correlated positively with pathological response. This study has important clinical implications for adjusting chemotherapy regimens.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Flavia Castellano, Armelle Prevost-Blondel, Jose L. Cohen, Valerie Molinier-Frenkel
Summary: Although IL4I1 has emerged as a relevant therapeutic target for cancer, its precise role remains poorly understood. IL4I1 inhibits TCR signaling, modulates T cell differentiation, limits T cell proliferation, and shapes the tumor microenvironment in a way that impairs the antitumor immune response. The production of new IL4I1 metabolites may play a role in activating the aryl-hydrocarbon receptor (AHR), but the correlation between IL4I1 expression and AHR activation in human cancers is weak.
Meeting Abstract
Immunology
B. Oriol-Tordera, A. Esteve-Codina, M. Berdasco, E. Goncalves, M. Esteller, T. Hanke, J. Molto, B. Clotet, M. L. Calle, B. Combadiere, A. Sanchez-Pla, B. Mothe, M. Ruiz-Riol, C. Brander
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
(2021)